Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05111301 · ClinicalTrials.gov registry record · NA
Control-IQ Technology in Individuals With Type 2 Diabetes
A NA study of Type 2 Diabetes Treated With Insulin, sponsored by Tandem Diabetes Care.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT05111301: Completed NA study of Type 2 Diabetes Treated With Insulin, sponsored by Tandem Diabetes Care.
NCT05111301 is a NA study of Type 2 Diabetes Treated With Insulin that has completed, run by Tandem Diabetes Care. The registered enrollment target is 30 participants, below the 299-participant average among 3 other Type 2 Diabetes Treated With Insulin trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05111301, a NA study of Type 2 Diabetes Treated With Insulin, has completed, sponsored by Tandem Diabetes Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
A prospective, multicenter study of 6 weeks of home use of Control-IQ technology in individuals with type 2 diabetes age 18 and older.
Primary Outcome
CGM-measured percentage below 54 mg/dl, compared to baseline
Conditions Studied
Interventions
- DEVICE Control-IQ technology 1.5
Study Locations (3)
Minnesota
- Mayo Clinic - Rochester
New York
- Icahn School of Medicine at Mt. Sinai - New York
Texas
- Texas Diabetes and Endocrinology - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2022-08-18 |
| Phase | NA |
What the finished NCT05111301 record still lists
NCT05111301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 299-participant average among 3 other Type 2 Diabetes Treated With Insulin trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Type 2 Diabetes Treated With Insulin appearing as the primary indexed condition, and to 1 intervention - of which Control-IQ technology 1.5 is the first listed.
NCT05111301 reports a single indexed study location in Minnesota, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT05111301 about?
NCT05111301 is a clinical study titled "Control-IQ Technology in Individuals With Type 2 Diabetes". A prospective, multicenter study of 6 weeks of home use of Control-IQ technology in individuals with type 2 diabetes age 18 and older.
What is the current status of trial NCT05111301?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-11-30. Estimated completion is 2022-08-18.
What conditions does trial NCT05111301 study?
This clinical trial studies the following conditions: Type 2 Diabetes Treated With Insulin.
What interventions are being tested in trial NCT05111301?
The interventions under investigation include: Control-IQ technology 1.5 (DEVICE).
Who is sponsoring clinical trial NCT05111301?
This trial is sponsored by Tandem Diabetes Care, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05111301 being conducted?
This trial has 3 study locations across Minnesota, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Treated With Insulin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI